C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Core Insights - C4 Therapeutics, Inc. has appointed Ron Cooper as the new chairman of its Board of Directors, aiming to enhance its transition into a fully integrated biotechnology company [1][3][7] - Bruce Downey, the previous chairman, will remain on the Board, while Glenn Dubin has stepped down [1][8] Company Leadership Changes - Ron Cooper brings extensive experience from his previous role as president and CEO of Albireo Pharma, and nearly 30 years at Bristol-Myers Squibb, where he was involved in several successful product launches [2][7] - The leadership transition is part of C4T's strategy to strengthen its Board with individuals who have deep expertise in various areas of biopharmaceutical development [8] Strategic Vision - The company is focused on advancing its pipeline in targeted protein degradation science, which has significant potential for developing new therapies [3][9] - C4T aims to leverage its TORPEDO® platform to design and optimize small-molecule medicines for challenging diseases, enhancing patient outcomes [9]